JPS6122018A - 癌免疫療法増強剤 - Google Patents

癌免疫療法増強剤

Info

Publication number
JPS6122018A
JPS6122018A JP59141081A JP14108184A JPS6122018A JP S6122018 A JPS6122018 A JP S6122018A JP 59141081 A JP59141081 A JP 59141081A JP 14108184 A JP14108184 A JP 14108184A JP S6122018 A JPS6122018 A JP S6122018A
Authority
JP
Japan
Prior art keywords
aspirin
cancer immunotherapy
salt
cancer
acetylsalicylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP59141081A
Other languages
English (en)
Japanese (ja)
Other versions
JPH047725B2 (https=
Inventor
Tsunetaka Nakajima
中島　常隆
Masahiro Watanabe
正弘 渡辺
Masayuki Nishida
正行 西田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
GC Biopharma Corp
Original Assignee
Green Cross Corp Japan
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Green Cross Corp Korea filed Critical Green Cross Corp Japan
Priority to JP59141081A priority Critical patent/JPS6122018A/ja
Publication of JPS6122018A publication Critical patent/JPS6122018A/ja
Publication of JPH047725B2 publication Critical patent/JPH047725B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP59141081A 1984-07-06 1984-07-06 癌免疫療法増強剤 Granted JPS6122018A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59141081A JPS6122018A (ja) 1984-07-06 1984-07-06 癌免疫療法増強剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59141081A JPS6122018A (ja) 1984-07-06 1984-07-06 癌免疫療法増強剤

Publications (2)

Publication Number Publication Date
JPS6122018A true JPS6122018A (ja) 1986-01-30
JPH047725B2 JPH047725B2 (https=) 1992-02-12

Family

ID=15283765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59141081A Granted JPS6122018A (ja) 1984-07-06 1984-07-06 癌免疫療法増強剤

Country Status (1)

Country Link
JP (1) JPS6122018A (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0914778A1 (en) * 1997-08-15 1999-05-12 Consolidated Nutrition, L.C. Oral administration of bacteria at a concentration which produces cell-mediated immunity and weight in certain animals
WO2003028758A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003028757A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US7030212B1 (en) 1998-07-31 2006-04-18 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gene WT1
US8105604B2 (en) 2001-03-22 2012-01-31 International Institute Of Cancer Immunology, Inc. WT1 modified peptide
US12297279B2 (en) 2019-06-04 2025-05-13 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0914778A1 (en) * 1997-08-15 1999-05-12 Consolidated Nutrition, L.C. Oral administration of bacteria at a concentration which produces cell-mediated immunity and weight in certain animals
US7030212B1 (en) 1998-07-31 2006-04-18 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gene WT1
US7390871B2 (en) 1998-07-31 2008-06-24 International Institute Of Cancer Immunology, Inc. Tumor antigen based on products of the tumor suppressor gene WT1
US7517950B2 (en) 1998-07-31 2009-04-14 International Institute Of Cancer Immunology, Inc. Tumor antigen based on products of the tumor suppressor gene WT1
US7608685B1 (en) 1998-07-31 2009-10-27 International Institute Of Cancer Immunology, Inc. Tumor antigen based on products of the tumor suppressor gene WT1
US8105604B2 (en) 2001-03-22 2012-01-31 International Institute Of Cancer Immunology, Inc. WT1 modified peptide
WO2003028758A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003028757A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US12297279B2 (en) 2019-06-04 2025-05-13 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis

Also Published As

Publication number Publication date
JPH047725B2 (https=) 1992-02-12

Similar Documents

Publication Publication Date Title
EP0726772B1 (en) A method for sensitization of cancer cells for killer cell mediated lysis
JP3140021B2 (ja) Ｔｎｆ阻害剤含有医薬組成物
EP0116693B1 (en) An immunopotentiator having spermidine or its pharmacologically acceptable salt as active ingredient
EP0752870B1 (en) Use of mycobacterium for the treatment of tumours
IT8922725A1 (it) Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
Schultz et al. Augmentation of specific macrophage-mediated cytotoxicity: correlation with agents which enhance antitumor resistance
JPS6122018A (ja) 癌免疫療法増強剤
Rios et al. Comparative effect of Mycobacterium bovis-and neuraminidase-treated tumor cells on the growth of established methylcholanthrene fibrosarcomas in syngeneic mice
WO2023134202A1 (zh) 脆弱拟杆菌荚膜多糖a与免疫检查点抑制剂联用在制备治疗消化系统肿瘤药物中的应用
Youn et al. Inhibition of C3H/He mouse mammary tumor growth by combined treatment with cyclophosphamide and polyadenylic-polyuridylic acid
EP0081882B1 (en) Medicine having transplant rejection and/or immunological inflammation inhibiting activities, as well as a method for inhibiting transplant rejection and/or immunological inflammation
Larionov Some biological and clinical results from the investigations of the chloroethylamines as anti-tumour drugs
JPH045005B2 (https=)
EP0352609B1 (en) Use of adenosine derivatives in preparing pharmaceutical compositions possessing immunostimulant activity
OKURA et al. Effect of forphenicinol on the production of Ia-positive macrophages in mice with or without L1210 leukemia and on the growth of L1210 in immunized mice
Pomeroy et al. Phenotypes, proliferative responses, and suppressor function of lung lymphocytes during Toxoplasma gondii pneumonia in mice
EP0522001B1 (en) Supportive use of linomide (r)
JPH059131A (ja) 抗癌剤
Sparks et al. Effect of Bacillus Calmette-Guérin on Immunosuppression from Cyclophosphamide, Methotrexate, and 5-Fluorouracil
Brenner Interleukin 2 and the treatment of leukemia and lymphoma
JPWO2001070251A1 (ja) 抗がん組成物
Golub Burkitt's Lymphoma Cells 1, 2
Hinev et al. BLADDER CANCER IMMUNOTHERAPY
JP2001288094A (ja) 細胞性免疫強化剤
EP0058857A2 (en) Hepatosin, process for preparing it and therapeutical composition containing hepatosin